secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-209253
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance
--------------------------------------------------------------------------------

- Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).
- DAYBUE STIX launch underway; ~30% of STIX patients treatment-naive or returning after liquid discontinuation.
- Phase 2 remlifanserin topline data in Alzheimer's disease psychosis expected Aug–Oct 2026, on track.
- Trofinetide Japan trial results anticipated Sep–Nov 2026; Delphi panel recommends DAYBUE as Rett syndrome standard of care.
- Reaffirms full-year 2026 financial guidance (no specific numbers provided).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/0001193125-26-209253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-209253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer